Key Highlights

Risk & Performance

Pipeline Risk Assessment

Based on historical performance

Moderate Risk

Score: 45/100

Failure Rate

17.9%

10 terminated/withdrawn out of 56 trials

Success Rate

77.3%

-9.2% vs industry average

Late-Stage Pipeline

64%

36 trials in Phase 3/4

Results Transparency

53%

18 of 34 completed trials have results

Key Signals

3 recruiting18 with results7 terminated

Enrollment Performance

Analytics

Phase 4

23(43.4%)

Phase 3

13(24.5%)

Phase 2

8(15.1%)

Phase 1

7(13.2%)

N/A

1(1.9%)

Early Phase 1

1(1.9%)

53Total

Phase 4(23)

Phase 3(13)

Phase 2(8)

Phase 1(7)

+2 more

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (56)

Showing 20 of 56 trials

NCT07235085Phase 3Recruiting

A Study to Evaluate the Efficacy and Safety of OTX-TKI (Axitinib Implant) in Participants With Non-Proliferative Diabetic Retinopathy

Role: lead

NCT04371445Phase 4Recruiting

Dextenza in the Post-op Management of Vitreoretinal Surgeries

Role: collaborator

NCT05023304Phase 4Completed

In Clinic Optometrist Insertion of Dextenza Prior to Cataract Surgery

Role: collaborator

NCT06495918Phase 3Active Not Recruiting

Study to Evaluate the Efficacy and Safety of Intravitreal OTX-TKI (Axitinib Implant) in Subjects With Neovascular Age- Related Macular Degeneration

Role: lead

NCT06223958Phase 3Active Not Recruiting

Study to Evaluate the Efficacy and Safety of Intravitreal OTX-TKI (Ocular Therapeutix) (Axitinib Implant) in Subjects With Neovascular Age-Related Macular Degeneration

Role: lead

NCT05335122Phase 2Completed

A Study to Evaluate the Efficacy and Safety of OTX-TIC (Travoprost) Intracameral Implant for Patients With Open-angle Glaucoma (OAG) or Ocular Hypertension (OHT)

Role: lead

NCT04527887Phase 4Terminated

Intracanalicular Dexamethasone Insert for the Treatment of Inflammation and Discomfort in Dry Eye Disease (DEcIDED)

Role: collaborator

NCT04360174Phase 1Completed

CLN-0045: Safety, and Efficacy of OTX-TIC in Participants With Open Angle Glaucoma or Ocular Hypertension

Role: lead

NCT04396990Phase 4Completed

The RESTORE Study, A Randomized, Controlled, Masked (Reading Center) Prospective Study

Role: collaborator

NCT05814757Phase 2Completed

OTX-DED for the Short-term Treatment of the Symptoms of Dry Eye Disease (DED)

Role: lead

NCT03630315Phase 1Completed

CLN-0046: Treatment of AMD Subjects With OTX-TKI

Role: lead

NCT04539548Phase 3Completed

A Study Assessing the Safety and Efficacy of Dextenza® for the Treatment of Ocular Pain and Inflammation Following Surgery for Pediatric Cataract

Role: lead

NCT04200651Phase 4Terminated

Prospective Study on DEXTENZA® Safety And Efficacy Following Concomitant MIGS and Cataract Surgery

Role: collaborator

NCT04168112Phase 4Completed

Intracanalicular Dexamethasone Insert for Post-Corneal Cross-Linking Inflammation and Pain- The LINK Study

Role: collaborator

NCT04989699Phase 1Completed

Study Evaluating the Treatment of OTX-TKI for Subjects With Neovascular Age-related Macular Degeneration

Role: lead

NCT05695417Phase 1Unknown

Study to Evaluate the Safety, Tolerability, and Efficacy of OTX-TKI in Subjects With Moderately Severe to Severe Non-proliferative Diabetic Retinopathy

Role: lead

NCT04362670Phase 1Completed

Study to Evaluate the Safety, Tolerability, and Efficacy of OTX-CSI in Subjects With Dry Eye Disease.

Role: lead

NCT05372315Phase 4Completed

Efficacy of Dextenza Insert in Upper vs Lower Punctum Following Cataract Surgery With PCIOL.

Role: collaborator

NCT04464629Phase 4Terminated

Assessing the Efficacy and Safety of DEXTENZA in Pseudo Phakic Patients Undergoing Gas Bubble Repair and Laser Following Retinal Detachment

Role: collaborator

NCT05143281Phase 4Completed

The SITE Study - Dexamethasone Ophthalmic Insert In OR on Day of Surgery Versus In-office Post-Op Day 1

Role: collaborator